loading...| Preferred Name | cabazitaxel | |
| Synonyms |
RPR-116258A taxoid XRP6258 1-hydroxy-7β,10β-dimethoxy-9-oxo-5β,20-epoxytax-11-ene-2α,4,13α-triyl 4-acetate 2-benzoate 13-[(2R,3S)-3-{[(tertbutoxycarbonyl]amino}-2-hydroxy-3-phenylpropanoate] Jevtana XRP6258 |
|
| Definitions |
A semi-synthetic derivative of the natural taxoid 10-deacetylbaccatin III with potential antineoplastic activity. Cabazitaxel binds to and stabilizes tubulin, resulting in the inhibition of microtubule depolymerization and cell division, cell cycle arrest in the G2/M phase, and the inhibition of tumor cell proliferation. Unlike other taxane compounds, this agent is a poor substrate for the membrane-associated, multidrug resistance (MDR), P-glycoprotein (P-gp) efflux pump and may be useful for treating multidrug-resistant tumors. In addition, cabazitaxel penetrates the blood-brain barrier (BBB). Check for "https://www.cancer.gov/about-cancer/treatment/clinical-trials/intervention/C66937" active clinical trials using this agent. ("http://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI%20Thesaurus&code=C66937" NCI Thesaurus) |
|
| ID |
http://purl.bioontology.org/ontology/PDQ/CDR0000534131 |
|
| altLabel |
RPR-116258A taxoid XRP6258 1-hydroxy-7β,10β-dimethoxy-9-oxo-5β,20-epoxytax-11-ene-2α,4,13α-triyl 4-acetate 2-benzoate 13-[(2R,3S)-3-{[(tertbutoxycarbonyl]amino}-2-hydroxy-3-phenylpropanoate] Jevtana XRP6258 |
|
| cui |
C1883567 C2830183 C5848333 C2927159 |
|
| DATE FIRST PUBLISHED |
2007-02-05 |
|
| Date last modified |
2010-06-18 |
|
| definition |
A semi-synthetic derivative of the natural taxoid 10-deacetylbaccatin III with potential antineoplastic activity. Cabazitaxel binds to and stabilizes tubulin, resulting in the inhibition of microtubule depolymerization and cell division, cell cycle arrest in the G2/M phase, and the inhibition of tumor cell proliferation. Unlike other taxane compounds, this agent is a poor substrate for the membrane-associated, multidrug resistance (MDR), P-glycoprotein (P-gp) efflux pump and may be useful for treating multidrug-resistant tumors. In addition, cabazitaxel penetrates the blood-brain barrier (BBB). Check for "https://www.cancer.gov/about-cancer/treatment/clinical-trials/intervention/C66937" active clinical trials using this agent. ("http://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI%20Thesaurus&code=C66937" NCI Thesaurus) |
|
| LT |
TRD |
|
| NCI ID |
C66937 |
|
| notation |
CDR0000534131 |
|
| ORIG STY |
Drug/agent |
|
| prefLabel |
cabazitaxel |
|
| tui |
T109 T121 |